Clinical trial · Interventional
Anal Crohn Fistula Surgery
A National, Multicenter, Randomized Open-Label Study of Proctological Surgery Efficacy on Anoperineal Fistulas Healing in Crohn's Disease Patients Treated With Adalimumab. (Official French Title: "Étude Nationale, Multicentrique, randomisée et en Ouvert de l'efficacité de la Chirurgie Proctologique Sur la Cicatrisation Des Fistules anopérinéales de la Maladie de Crohn Chez Des Patients traités Par Adalimumab")
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to demonstrate, in patients treated with adalimumab, the efficacy of proctological surgery in anoperineal fistula healing after the removal of seton drain.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anal Fistula | — | UNRESOLVED | — |
| Anoperineal Fistula | — | UNRESOLVED | — |
| Crohn Disease | — | UNRESOLVED | — |
| Fistula | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| All types of surgery procedures | Procedure | — | UNRESOLVED |
| Simple seton drain removal | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Surgery
- description
- Seton drain removal is associated with proctological surgery.
- interventionNames
- Procedure: All types of surgery procedures
- type
- OTHER
- label
- Simple seton drain removal
- interventionNames
- Procedure: Simple seton drain removal
Primary outcomes (1)
- measure
- Percentage of patients having a clinical healing of their anoperineal fistulas in Crohn disease
- timeFrame
- 12 months after seton drain removal
Secondary outcomes (7)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * male or female 18 years or older, * women of childbearing age who use an effective contraception method or women incapable of becoming pregnant \[(i.e. postmenopausal women for 1 year or surgically sterile (hysterectomy and/or bilateral oophorectomy)\], * Patient with fistulizing anoperineal Crohn's disease. Anoperineal fistulas can be associated with ileal, colic or rectal lesions, * Patient with at least 1 anoperineal fistula drained with a seton for more than 1 month, * Patient treated with adalimumab for more than 1 month, * Patient who agrees to undergo surgery for its drained fistula(s), * Patient with immunosuppressive therapy (azathioprine, 6-mercaptopurine ou methotrexate) stable for at least 3 months or patients without immunosuppressive therapy, * Patient who gave signed written informed consent after having received verbal explanation and written information related to the trial. Exclusion Criteria: * Pregnant or breastfeeding women, * Patient having a perineal abscess, * Patient with a high anovaginal fistula that cannot be treated, according to the investigator ,with fistulotomy, gluing, biodegradable plug or advancement flap, * Patient treated with a daily dose of corticosteroids of more than 20 mg (a dose of more than 20 mg daily will be authorized during the study), * Contraindication to proctological surgery on the drained fistula(s), * Patient presenting with somatic or psychic signs or symptoms that are not compatible with his/her participation in the trial according to the investigator, * Patient who participate in another clinical trial.
References
Publications (1)
- DERIVEDAbramowitz L, Brochard C, Pigot F, Roumeguere P, Pillant H, Vinson Bonnet B, Faucheron JL, Senejoux A, Bonnaud G, Meurette G, Fayette JM, Train C, Staumont G, Siproudhis L, Bouchard D. Surgical closure, mainly with glue injection and anti-tumour necrosis factor alpha, in fistulizing perianal Crohn's disease: A multicentre randomized controlled trial. Colorectal Dis. 2022 Feb;24(2):210-219. doi: 10.1111/codi.15947. Epub 2021 Oct 23. PMID 34623746